Yuhan
| Market cap | ₩5.5T |
| PE ratio | 25.35 |
| Forward PE | 35.55 |
| PB ratio | 2.32 |
| EPS | ₩2,927 |
| Dividend (yield) | ₩600 (0.81%) |
| Analysts (1–5) | 4.00 · Buy |
| Price target | ₩121,563 (+64.05%) |
| Volume | 117,908 |
| Trading value | ₩8.7B |
| Day’s range | ₩73,300 – ₩75,500 |
| 52-week range | ₩65,000 – ₩129,200 |
| Foreign ownership KR | 20.95% |
| Foreign net buy (Oct 2) KR | −9,229 sh |
| Book value / share | ₩31,931 |
| Founded | 1926 |
Close (KRW) Foreign ownership, % of shares (right axis)
Foreign, institutional and retail net buying KR data
Shares by trading day; positive means net buying. Korea publishes investor-type flows for every stock — global sites such as Yahoo or StockAnalysis do not show them.
| Date | Close | Foreigners | Institutions | Retail | Foreign ownership |
|---|---|---|---|---|---|
| Oct 2 | ₩74,100 | −9,229 | −20,512 | +29,410 | 20.93% |
| Oct 1 | ₩74,800 | +18,894 | −8,806 | −9,952 | 20.95% |
| Sep 30 | ₩72,800 | +14,060 | −10,835 | −3,601 | 20.95% |
| Sep 29 | ₩73,000 | +7,222 | −55,041 | +46,779 | 20.89% |
| Sep 28 | ₩74,700 | +32,883 | −27,210 | −5,673 | 20.72% |
Financials
Annual, consolidated where available, KRW. Columns ending in E are analyst consensus estimates. Source: company filings (DART) via Naver Finance.
| Item | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|
| Revenue | ₩1.9T | ₩2.1T | ₩2.2T | ₩2.3T |
| Operating income | ₩57.0B | ₩54.9B | ₩104.4B | ₩128.9B |
| Net income | ₩134.2B | ₩55.2B | ₩185.3B | ₩150.0B |
| Operating margin | 3.07% | 2.65% | 4.77% | 5.49% |
| Return on equity | 6.75% | 3.40% | 8.81% | 6.91% |
| Debt-to-equity | 33.88% | 36.80% | 36.35% | – |
| EPS | ₩1,673 | ₩869 | ₩2,389 | ₩2,087 |
| Dividend per share | ₩430 | ₩500 | ₩600 | ₩600 |
Peers
| Samsung Biologics 207940 | ₩1,354,000 | −4.51% |
| Celltrion 068270 | ₩182,600 | −0.54% |
| Samsung Epis Holdings 0126Z0 | ₩365,000 | −2.28% |
| Hanmi Pharm 128940 | ₩506,000 | +1.71% |
| SK Biopharmaceuticals 326030 | ₩75,800 | −1.17% |
| Sam Chun Dang Pharm 000250 | ₩207,000 | +3.81% |
About
Yuhan, founded in 1926 and listed on the KOSPI in 1962, makes and sells pharmaceuticals, chemicals, industrial and veterinary drugs, and household goods. Its drug business includes a non-small cell lung cancer treatment, its healthcare unit sells household products, and its overseas unit exports active ingredients for HIV and hepatitis C drugs. It has two main subsidiaries.
Yuhan Corporation is listed on the KOSPI market of the Korea Exchange under the ticker 000100. Industry: Pharmaceuticals.
Direct KRX access through a global broker, a US-listed ADR where one exists, or a Korea ETF — compared in our guide.
Data: Korea Exchange closing prices, investor flows and foreign ownership via Naver Finance; company information from DART (Financial Supervisory Service). Updated after each Korean market close; ratios and flows as of Oct 2, 2026. Delayed data, not investment advice.